Rationale, aims, and objectives: Prolongation of the corrected QT (QTc) interval is associated with increased morbidity and mortality.
lengthening, 39 and 12 milliseconds, respectively. In the absence of risk factors, Known QTPMs and ≥2 QTPMs were associated with modest but greater QTc lengthening than Possible or Conditional QTPMs. In the presence of risk factors, ≥2 QTPM further increased QTc lengthening.
In combination with risk factors, the association of all QTPM categories with QTc lengthening was greater than QTPMs alone.
Conclusion: Risk factors, particularly female sex and history of prolonged QTc interval, have stronger associations with QTc interval lengthening than any QTPM category alone. All QTPM categories augmented QTc interval lengthening associated with risk factors.
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| INTRODUCTION
Prolongation of the heart rate corrected QT (QTc) interval on electrocardiogram (ECG) has been linked to adverse outcomes, including torsade de pointes (TdP) and sudden cardiac death. [1] [2] [3] [4] [5] [6] Several independent risk factors for QTc interval prolongation have been identified, including numerous medications. 7, 8 The association between the magnitude of QTc interval lengthening and QTc interval-prolonging medications (QTPMs) and other risk factors, individually and in combination, is currently unknown. Up to 25%
of insured outpatients receive at least one potential QTPM, and up to 10% may also receive an interacting medication. [9] [10] [11] In addition to the increasing number of available medications with the potential to prolong the QTc interval, many medications have recently suffered revised drug labelling or have been withdrawn from the market because of evidence linking these medications with TdP. 1, [12] [13] [14] [15] [16] [17] [18] [19] [20] Furthermore, health care providers frequently prescribe QTPMs in patients who already have multiple risk factors for QTc lengthening. 10, 21 This may be further complicated when both cardiovascular and noncardiovascular QTPMs (eg, antidepressants and anti-infectives) are prescribed. [22] [23] [24] [25] Based upon existing data, a prescriber is unable to estimate the potential magnitude of QTc interval lengthening provoked by a QTPM in association with existing risk factors for The medication survey is a part of the core data collection and was conducted by trained interviewers; the survey was introduced during the first examination and continued to be administered to all participants through visit 4. Patients were asked to bring all prescription and over-the-counter medications to each visit. The medication survey and ECG were obtained at this similar visit. The QT interval from the digital 12-lead ECG was determined by the NOVACODE program.
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The NOVACODE program generates an average waveform derived from all 12 simultaneously measured leads. This allows the system to determine the QT from the earliest QRS onset to the latest offset of the T-wave. All ECG waveforms were verified by visual inspection as part of the standard ARIC protocol, and a globally averaged QT interval was generated from the earliest QRS onset and T-wave offset using all leads. 28 The ARIC study has been approved by the Institutional Review
Boards of all participating institutions. Participants provided written informed consent at each ARIC study visit.
The ARIC study assessed all participants with a resting, standard • Selected risk factors known to prolong QTc: age ≥ 65 years, female sex, left ventricular hypertrophy (LVH) and prolonged QTc (QTc > 500 ms) observed previously (ie, at the prior visit for this analysis). 29, 30 Corrected QT was not observed prior to visit 1, so all visit 1 observations were dropped from the analysis.
• Corrected QT interval using Bazett (QTc Baz ) and Framingham 
an indicator variable for having one or more risk factors (age ≥ 65 years, female gender, LVH, prior QTc > 500 ms). The assessment of the change due to the combination of risk factors and use of QTPM was calculated as the combined effects of the medication categorization, the risk factor, and the interactive effect between the medication categorization and having one or more risk factors. All models used visit indicators to control for changes over time including changes in prescribing behaviours (or entry or exit of medications to the market) separate from aging. Although use of QTPM was chosen by the participant or their medical provider, we did not adjust for treatment selection (confounding by indication), 35 so all estimations reflect statistical associations rather than causal effects. Cluster-robust standard errors were used to account for multiple observations per cohort member.
| RESULTS
The use of QTPMs increased from 8% at visit 1 to 17% at visit 4 ( Figure 1 ). This increase could be due to changes in prescribing patterns as well as aging. The use of QTPMs with varying risk of TdP (Known, Conditional, and Possible) differed across visits. At visits 1 through 4, prescribing of Conditional QTPMs was most common (6%, 8%, 12%, and 13%, respectively) followed by Known and then Possible.
The distribution was slightly different among participants using two or more QTPMs, Known was the most frequent QPTM followed by Conditional. 4 (1990-1998) .
The regression included 3 additional variables: interactions between the 3 medication categorizations and having one or more risk factor. (See Table 3 ). use without any risk factors were not associated with a statistically significant increase in QTc Baz . In the presence of risk factors, ≥2 QTPM further increases QTc lengthening. In Table 2 , the estimated effects for QTc Fram were generally less than for QTc Baz and; however, statistical significance was similar for most all endpoints measured by both equations. Table 3 and Figure 2 show the combined effects and 95% CIs from having risk factors in each of the QTPM medication categories, including an interactive effect between having one or more risk factor and the medication category. For each QTPM category, every risk factor was associated with increased QTc interval lengthening beyond that which was observed with QTPMs and no risk factors.
Substantial portions of the effect on QTc interval lengthening come from the individual risk factors (effects shown in Table 2 ) rather than the medication effect or interaction effects. The highest magnitudes of QTc interval lengthening were observed in participants receiving
QTPMs in addition to having prior QTc > 500 milliseconds (increases in QTc from 40 to 46, depending on QTc medication category and correction formula).
| DISCUSSION
Our study is the first to determine the relative associations of selected risk factors for QTc interval lengthening with different categorizations of QTPMs on the QTc interval in a community-based cohort. Approximately 80% of participants had at least one risk factor for QTc interval lengthening with prior QTc > 500 milliseconds being associated with the most substantial lengthening. In addition, our results suggest that approximately 8% to 17% of community-dwelling adults use at least one QTPM and use increases with age. Our findings complement prior literature showing that nearly 5% to 10% of community-dwelling adults receive at least one QTPM. 10, 11 Conditional QTPMs were the most commonly used QTPMs in this study sample, followed by Known and Possible QTPMs. In participants with no risk factors, the use of Known QTPMs or ≥2 QTPMs was associated with the highest magnitude of QTc lengthening. In combination with risk factors, the association of all QTPM categories with QTc lengthening was greater than QTPMs alone.
Although risk factors had a greater association with QTc interval lengthening than QTPMs alone, the magnitude of QTc lengthening increases when risk factors are combined with QTPMs.
History of prolonged QTc interval was associated with the greatest degree of QTc interval lengthening. These findings should assist prescribers of QTPMs and more narrowly focus screening and monitoring to selected patients at high risk.
Our study has several limitations. Coefficient estimates come from the same regression as in Table 2 : n = 36 602 person-visits occurring between visit 2 and visit 4 (1990-1998 b Differences were calculated as the coefficient for the risk factor plus the coefficient for the interaction between the QTPM category and having one or more risk factors. For example, the change for females taking a Known QTPM was calculated by adding the coefficient for female and the coefficient for the interaction of Known QTPM with having one or more risk factor. In this example, the reference group is individuals with no risk factors that are taking a Known QTPM.
*Difference is significant at P < 0.05. Visit 1 sample is limited to persons who also participated in visit 2 (the first visit used in the regression). The error bars show the 95% confidence interval. The horizontal axis shows the 3 different QTPM categories and no QTPM. The vertical axis shows the change in the QTc interval from the prior visit in milliseconds. The changes were calculated by combining coefficients from the QTPM category, the risk factor, and an interaction of the QTPM category with having one or more risk factor. For example, the change for females taking a Known QTPM was calculated by adding the coefficient for Known QTPMs, the coefficient for female, and the coefficient for the interaction of Known QTPM with having one or more risk factors. The reference group for all changes is individuals with no risk factors that are not taking any QTPMs
